Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial
Oncolytics Biotech reports sustained clinical benefit with pelareorep immunotherapy in second-line RAS-mutant MSS colorectal cancer patients.
Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC
Nuvation Bio reports $18.5M Q1 2026 revenue for IBTROZI (taletrectinib) with majority of 200 new patients being TKI-naïve ROS1+ NSCLC cases.
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins as Strategic Adviser for DCVax Cancer Vaccine Development
Northwest Biotherapeutics names Dr. Annalisa Jenkins as Strategic Adviser to advance DCVax dendritic cell cancer vaccine platform with 25+ years biopharma experience.
FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
FDA's Oncologic Drugs Advisory Committee recognizes favorable benefit-risk profile for TRUQAP (capivasertib) in PTEN-deficient metastatic prostate cancer treatment.
Telix Pharmaceuticals' TLX101-Px (Pixlumi) Brain Cancer Imaging Drug Accepted for European Review
Telix Pharmaceuticals' TLX101-Px (Pixlumi) glioma imaging drug enters 210-day European regulatory review after MAA acceptance, targeting brain cancer diagnosis.
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
EC grants marketing authorization for POHERDY (pertuzumab), the first approved biosimilar to PERJETA in Europe, developed by Henlius Biotech and Organon.
PureTech Reports Positive LYT-200 Clinical Results for Myeloid Malignancies in 2025 Annual Results
PureTech announces positive clinical results for LYT-200 in myeloid malignancies, alongside Phase 3-ready deupirfenidone and advancing neuropsychiatric pipeline.
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
Silexion Therapeutics successfully submits Phase 2/3 clinical trial application to Germany's BfArM for SIL204, targeting KRAS-driven pancreatic cancer.
EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment
European Medicines Agency issues positive opinion for Viatris' generic palbociclib, potentially expanding access to this important breast cancer treatment.
RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results
RenovoRx announces ASCO acceptance of pharmacokinetic data from Phase III TIGeR-PaC trial testing TAMP therapy platform for pancreatic cancer treatment.
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.